Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine

Wolfgang Hg Laux, Stephane Priet, Karine Alvarez, Suzanne Peyrottes, Christian Perigaud

To cite this version:


HAL Id: hal-02094536
https://hal-amu.archives-ouvertes.fr/hal-02094536
Submitted on 9 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine

Wolfgang HG Laux1, Stéphane Priet2, Karine Alvarez2, Suzanne Peyrottes1 and Christian Perigaud1

Abstract

Background: The replacement of β,γ-pyrophosphate by β,γ-phosphonate moieties within the triphosphate chain of 5'-triphosphate nucleoside analogues was previously studied for various antiviral nucleoside analogues such as AZT and 2',3'-dideoxynucleosides. Thus, it has been shown that these chemical modifications could preserve, in some cases, the terminating substrate properties of the triphosphate analogue for HIV-RT. Herein, we aimed to study such 5'-triphosphate mimics based on the scaffold of the well-known antiviral agent 9-[(2-phosphonomethoxy)ethyl]adenine (PMEA, Adefovir).

Methods: Synthesis involved coupling of a morpholidate derivative of PMEA with appropriate pyrophosphoryl analogues. The relative efficiencies of incorporation of the studied diphosphate phosphonates were measured using subtype B WT HIV-1 RT in an in vitro susceptibility assay, in comparison to the parent nucleotide analogue (PMEApp).

Results: Searching for nucleoside 5'-triphosphate mimics, we have synthesized and studied a series of diphosphate analogues of PMEA bearing non hydrolysable bonds between the and phosphorus atoms. We also examined their relative inhibitory capacity towards HIV-1 reverse transcriptase in comparison to the parent nucleotide analogue (PMEApp). Only one of them appeared as a weak inhibitor (IC50 = 403.0 ± 75.5 μM) and proved to be less effective than PMEApp (IC50 = 6.4 ± 0.8 μM).

Conclusion: PMEA diphosphoryl derivatives were designed as potential substrates and/or inhibitors of various viral polymerases. These modifications dramatically affect their ability to inhibit HIV-RT.

Keywords
(phosphomethoxy)ethyl]adenine, phosphonate diphosphate analogues, HIV-1 reverse transcriptase, antiviral

Introduction

The acyclic nucleoside phosphonate 9-[(2-phosphomethoxy)ethyl]adenine (PMEA, Figure 1) exhibits a broad-spectrum activity against different types of DNA viruses and retroviruses. Its orally bioavailable form, the bis(pivaloyloxyethyl) prodrg (bis(POM)PMEA, Adefovir dipivoxil), has been approved for the treatment of chronic hepatitis B and other types of prodrugs are still under investigations. To achieve its inhibitory effect on viral synthesis, PMEA must be converted intracellularly to its active diphosphorylated metabolite, PMEApp (Figure 1). PMEApp has been described to interact as an alternative substrate and as a competitive inhibitor of both herpes simplex type 1 (HSV-1) DNA polymerase and reverse transcriptases. Variable inhibitory effects on human cellular DNA polymerases were observed, especially against DNA polymerase for which KI value was in the same range as dATP.
When compared to the affinity of PMEApp for HIV-RT (with $K_i$ value in the nanomolar range), it may explain the antiviral selectivity of parent phosphonate.

As part of a research program, we decided to synthesize new nucleoside 5'-triphosphate mimics based on the PMEA scaffold and incorporating chemical modifications of the $Pb–O–Pc$ phosphoester bonds. Replacement of the anhydride oxygen with isosteric groups leading to non-hydrolysable bonds, the resulting analogues were designed as biological tools for the study of substrate properties of cellular and/or viral enzymatic systems, as well as new potential therapeutic agents. Based on previously published works on related topic, requirements in the design of modified triphosphate analogues emerged: (i) the anhydride bond between $\beta$- and $\gamma$-phosphates, which is unaffected during the DNA biosynthesis, could be replaced with non-hydrolysable bond; (ii) similar modification could also be introduced between the 5'-position of sugar and the phosphorus atom; (iii) the anhydride bond between $\alpha$- and $\beta$-P atoms should be preserved in order to provide the possibility of the mimetic to interact with targeted polymerase as substrate.

In this respect, PMEApp constitutes an attractive model to study chemical modifications on the pyrophosphoryl residue due to its phosphonate structure, characterized by a stable P–C bond (toward phosphohydrolase-hydrolysis) between acyclic nucleoside moiety and $\alpha$-phosphorus atom, and its broad and high affinity for viral polymerases. Herein, we report the full accounts of the synthesis of compounds 1b-j and their study as terminating substrates in the DNA chain elongation catalyzed by human immunodeficiency virus (HIV) reverse transcriptase.

**Experimental section**

**Material and methods**

$^1$H NMR (250 MHz) and $^{13}$C NMR (100 MHz) spectra were recorded with proton decoupling at ambient temperature. Chemical shifts ($\delta$) are quoted in parts per million (ppm) referenced to the residual solvent peak chloroform (CDCl$_3$) at 7.26 ppm and 77.0 ppm, deuterium oxide (D$_2$O) at 4.63 ppm relative to tetramethysilsilane (TMS). COSY experiments were performed in order to confirm proton assignments as well as 2D $^1$H-$^13$C heteronuclear COSY for the attribution of $^{13}$C signals. $^{31}$P NMR spectra were recorded at ambient temperature at 100 MHz. Chemical shifts are reported relative to external phosphoric acid (H$_3$PO$_4$). $^{19}$F NMR spectra were recorded at ambient temperature at 235 MHz. Chemical shifts are reported relative to external trichlorofluoromethane (CFCl$_3$). Coupling constants, $J$, are given in Hertz. FAB mass spectra were recorded in the negative-ion mode using glycerol/thioglycerol (1:1, v/v, G-T) as matrix. Only nominal mass of ions corresponding to the mass of the lightest chlorine or bromine isotopes is given. However, the halogen-isotope peak intensity patterns were ascertained and they agreed with the formula of the ions. Thin layer chromatography was performed on precoated aluminum sheets of Silica Gel 60 F$_{254}$ (Merck, Art. 5554), visualization of products was accomplished by UV absorbance followed by spraying with Hanes molybdate reagent. Column chromatography was carried out on Silica Gel 60 (Merck, Art. 9385). Analytical HPLC studies were performed using a reverse-phase analytical column (Nucleosil, C18, 150 × 4.6 mm, 5 m) equipped with a prefilter, a precolumn (Nucleosil, C18, 5 m), and a photodiode array detector. Compounds were eluted under isocratic conditions with 0.4% acetonitrile in 50 mM triethylammonium acetate buffer with a flow rate of 1 mL/min. All moisture sensitive reactions were carried out in anhydrous conditions under argon atmosphere using oven-dried glassware. Solvents were dried and distilled prior to use and solids were dried over P$_2$O$_5$ under reduced pressure at rt.

**Chemistry**

9-[(2-Phosphomethoxy)ethyl]-adenine (PMEA) and its phosphoromorpholidate derivative 2 were synthesized according to a published procedure. The tributylammonium salts of pyrophosphate 3a and diphosphonic acids 3b-d were obtained from their commercially available forms: tetra sodium pyrophosphate decahydrate, tetra sodium imidodiphosphonate, methanediphosphonic acid and 1-hydroxyethylidene diphosphonic acid, respectively. The halomethylidene diphosphonic acids 3e-j were obtained from their ethyl esters precursors following a usual way and stored as sodium forms after passage over a Dowex 50WX2 cation exchange resin column and freeze-drying. Tetraethyl...
methylenediphosphonate 4 was commercially available. The halomethylene diphosphate esters 5e, 5g, 6f and 6h were prepared using literature methods.20 Detailed description of experimental procedures and compound characterization are provided as supplementary data.

**In vitro drug susceptibility assays with recombinant subtype B WT HIV-1 RT**

The p66RTB gene construct allowing the bacterial expression of the wild-type (WT) HIV-1 RT was described elsewhere.21,22 The recombinant clade B WT HIV-1 RT was co-expressed with HIV-1 protease in *Escherichia coli* in order to obtain p66/p51 heterodimers, which were later purified using affinity chromatography. Enzymes were quantitated by active-site titration before biochemical studies.

Standard RT activity was assayed using 250 μg/mL of activated calf thymus DNA (GE Healthcare). To determine IC50 values, reactions were performed with 10 nM enzyme and 5 μM each dNTP as a mixture (dATP, dCTP, dGTP, dTTP) containing 100 μCi/mmole of [3H]-labelled deoxythymidine 5'-triphosphate (Perkin Elmer), for 15 min with increasing amounts of phosphonate, compounds 1a (PMEApp as reference), 1c, 1e to 1j. Each aliquot was spotted in duplicate on DE81 ion-exchange paper discs. Paper discs were washed twice with 0.3 M ammonium formate, pH 8.0, twice with water and once with ethanol, and then dried and transferred into sample bags. Scintillation fluid was added and the radioactivity bound to the discs was determined by liquid scintillation counting with MicroBeta Trilux Counter. Values of IC50 are the average from at least three independent experiments and were determined using Kaleidagraph data.

**Molecular modeling of HIV-1 RT in complex with diphosphate phosphonate analogues 1c, 1e, 1g, 1i**

All models were based on the X-ray structure of the RT in complex with dsDNA and incoming PMPApp (PDB code 1T05). The UCSF Chimera software (PMID: 15264254) was used to replace the PMP – moiety by the PME – equivalent. Moreover, the oxygen of the β,γ bridge of the diphosphate phosphonate PMPApp was replaced by CH2 (compound 1c), CCl2 (compound 1e), CBr2 (compound 1g) and CF2 (compound 1i) groups.

**Results**

The synthesis of PMEA diphosphate 1a and its mimetics 1b-j was carried out according to a general procedure (Scheme 1),23,24 which requires preliminary preparation of the phosphoromorpholidate derivative 2 of PMEA. This was accomplished by usual reaction of PMEA with morpholine and N,N'-dicyclohexylcarbodiimide as activating agent.18 Isolated as its 4-morpholine N,N'-dicyclohexylcarboxamidinium salt, 2 was further condensed with the appropriate tributylammonium salts of the diphosphonic acids 3b-j. The imido- and methylene-diphosphonate reagents 3b-d were commercially available as sodium or acidic forms. The halomethylidene diphosphonic acids 3e-h were prepared from the commercial tetraethyl methylenediphosphonate, following a published procedure.20 Preparation of the fluorinated diphosphonic acids 3i, j has previously been described from direct halogenation of tetra alkyl methylenediphosphonates19 or nucleophilic substitution of an appropriate halomethylphosphonate derivative by a phosphate anion.25–27

Moreover, in contrast to the dichloro- and dibromo-analogues (3e-h), nucleophilic dehalogenation of difluoromethylene-diphosphonates into the corresponding monofluoro esters by conventional methods28,29 was unsuccessful. In such conditions, P–C bond cleavage was observed resulting in the formation of dialkyl difluoromethylphosphonates. Thus, we decided to select the first approach (i.e. direct halogenation) leading in one step to a mixture of the mono- and difluoro- compounds through reaction of electrophilic fluorinating reagents with the carbanions.

![Scheme 1](image-url)  
**Scheme 1.** Final step in the synthesis of PMEApp 1a, and target diphosphate analogues 1b-j.
of alkyl methylidenediphosphonates. Reported methodologies used perchloryl fluoride or acetyl hypofluorite. Herein, N-fluorobenzenesulfonyl chloride was chosen as commercially available and easy handling fluorinating reagent. Consequently, tetraethyl methylenediphosphonate 4 was deprotonated by the action of potassium tert-butoxide and treated with N-fluorobenzenesulfonyl chloride (Scheme 2). Purification of the resulting mixture on flash silica gel chromatography yielded 29% of the starting material 4 and 31% of each desired mono- and dihalogenated species 5i and 6j, respectively. Saponification of the tetraethyl fluoromethylenediphosphonate esters 5i and 6j was carried out using bromotrimethylsilane to give rise to the fluorinated diphosphonic acids 3i, j.

Crude reaction of the phosphoromorpholidate derivative of PMEA 2 with pyrophosphate 3a or the appropriate tributylammonium salts of the diphosphonic acids 3b-j (Scheme 1) was firstly purified by a Dowex 1×2 chromatography using a gradient of aqueous lithium chloride in 0.01 M hydrochloric acid. Then, DEAE-Sephadex A25 chromatography gave PMEA diphosphate 1a and its mimetics 1b-j. The target diphosphate analogues 1b-j were isolated as lithium forms in 18–65% yields.

Table 1. Selected $^{31}$P NMR data of the new PMEA diphosphate mimetics 1b-j.

<table>
<thead>
<tr>
<th>Compound</th>
<th>$\delta P_{\alpha}$</th>
<th>$\delta P_{\beta}$</th>
<th>$\delta P_{\gamma}$</th>
<th>$^2J_{\alpha\beta}$</th>
<th>$^2J_{\beta\gamma}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>9.4</td>
<td>19.6</td>
<td>4.3</td>
<td>24.9</td>
<td>18.1</td>
</tr>
<tr>
<td>1b</td>
<td>9.7</td>
<td>6.2</td>
<td>0.7</td>
<td>25.6</td>
<td>5.2</td>
</tr>
<tr>
<td>1c</td>
<td>9.2</td>
<td>14.7</td>
<td>13.7</td>
<td>29.2</td>
<td>7.5</td>
</tr>
<tr>
<td>1d</td>
<td>9.9</td>
<td>16.4</td>
<td>17.6</td>
<td>36.1</td>
<td>32.2</td>
</tr>
<tr>
<td>1e</td>
<td>9.8</td>
<td>3.9</td>
<td>9.5</td>
<td>34.9</td>
<td>15.8</td>
</tr>
<tr>
<td>1f</td>
<td>9.4</td>
<td>7.9</td>
<td>10.3</td>
<td>31.1</td>
<td>5.2</td>
</tr>
<tr>
<td>1g</td>
<td>9.8</td>
<td>4.2</td>
<td>9.3</td>
<td>34.4</td>
<td>13.3</td>
</tr>
<tr>
<td>1h</td>
<td>9.3</td>
<td>7.1</td>
<td>9.9</td>
<td>31.2</td>
<td>3.9</td>
</tr>
<tr>
<td>1i</td>
<td>10.1</td>
<td>3.8</td>
<td>3.9</td>
<td>33.8</td>
<td>59.0</td>
</tr>
<tr>
<td>1j</td>
<td>9.5</td>
<td>6.8</td>
<td>8.6</td>
<td>31.3</td>
<td>12.2</td>
</tr>
</tbody>
</table>

Table 2. Selected $^{13}$C and $^{19}$F NMR data of the new PMEA diphosphate mimetics 1c-j.

<table>
<thead>
<tr>
<th>Compound</th>
<th>$\delta C$</th>
<th>$\delta F$</th>
<th>$^2J_{FC}$</th>
<th>$^2J_{FP_{\beta}}$</th>
<th>$^2J_{FP_{\gamma}}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1c</td>
<td>30.8</td>
<td>72.4</td>
<td>273.7</td>
<td>87.7</td>
<td>79.4</td>
</tr>
<tr>
<td>1d</td>
<td>78.0</td>
<td>49.5</td>
<td>180.5</td>
<td>64.8</td>
<td>55.6</td>
</tr>
<tr>
<td>1e</td>
<td>57.4</td>
<td>38.2</td>
<td>180.5</td>
<td>64.8</td>
<td>55.6</td>
</tr>
<tr>
<td>1f</td>
<td>118.7</td>
<td>218.6</td>
<td>180.5</td>
<td>64.8</td>
<td>55.6</td>
</tr>
<tr>
<td>1g</td>
<td>89.3</td>
<td>218.6</td>
<td>180.5</td>
<td>64.8</td>
<td>55.6</td>
</tr>
</tbody>
</table>

Discussion

The synthesis of new mimics of PMEApp incorporating non-hydrolysable bond between the $\beta$- and $\gamma$-P atoms has been carried out by reaction of the morpholidate derivative of PMEA 2 with the appropriate diphosphinic acids 3b-j (Scheme 1). The target diphosphate analogues 1b-j were isolated as lithium forms in 18–65% yields.

The $^{31}$P NMR spectra of the mimic phosphonates 1b-j showed characteristic downfield shifts which permitted, from a straightforward comparison with literature data, the direct assignment of resonances for $\alpha$-, $\beta$- and $\gamma$-P.
Finally, a single fluorine resonance was observed in $^{19}$F atoms, previously reported in other series for difluoromethylene interaction between... constant. In contrast, the $^{2}$J$^{\beta\gamma}$ coupling constant for the... compounds $^{1}$b-j showed substrate properties towards HIV-1 reverse transcriptase till the concentration of 100 M (as example IC$_{50}$ values for $^{1}$a and $^{1}$l were 6.4 ± 0.8 μM and 403 ± 75 μM, respectively).

Indeed, it has been previously shown in various nucleotide series that chemical modifications on 5'-phosphate residues could preserve, in some cases, electrostatic interactions with K65, counterbalancing the steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance.

Several factors including size, polarity, and electronegativity may modulate the activity, even so a certain tolerance of the HIV-1 reverse transcriptase to the $^{\gamma}$-P-substituents was demonstrated in literature.

To understand why diphosphate phosphonates analogues $^{1}$c, $^{1}$e, $^{1}$g and $^{1}$l are poor substrates of HIV-1 RT in comparison to PMEApp $^{1}$a, we performed modeling replacing the oxygen of the $^{\beta\gamma}$-bond by an electronegative group. According to Tuske et al., amino acids R72 and K65, and D113 to a lesser extent, play a key role in the binding of the nucleotide in the active site and in their incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance. However, the interaction with K65 (protonated form in the catalytic site) is lost and is responsible for nucleotide destabilization and discrimination. Indeed, the modification of its binding at the RT active site misaligns reactive centers and hampers the nucleophilic attack at the catalytic step of incorporation by HIV-1 RT (Figure 2(a)). If the substitution of oxygen atom of the $^{\beta\gamma}$-pyrophosphate bond by a methylene group (CH$_{2}$), i.e., compound $^{1}$c (Figure 2(b)), does not cause steric hindrance.
data from complexes of HIV-RT with purine or pyrimidine nucleotides. With purine nucleotides, as PMPApp, the amino acid R72 plays a crucial role in stacking the nucleobase, while only the amino acid R65 interacts with the O of the β,γ bridge. With pyrimidine nucleotides, their binding in the RT active site is slightly different, both amino acids R72 and K65 interact with the O of the α,β bridge and consequently the binding of the nucleotide is less sensible to the chemical modification of the bridge. This may explain why the modified phosphonate analogues of AZT are recognized and substrates for HIV-1 RT. Thus, they are efficiently incorporated in the growing nucleic acid chain.

Figure 2. (a) Structure of HIV-1 RT active site in complex with PMPApp. (b), (c), (d) and (e) models for the putative positioning of acyclic diphosphate phosphonates 1c, 1e, 1g, 1i in the active site of HIV-1 RT. The atomic coordinates (PDB 1T05 – HIV-1 RT in complex with PMPApp) were used to visualize the complex HIV-1 RT- diphosphate phosphonate, after modeling, replacing PMP-moiety by PME-one and the oxygen of the bridge of the diphosphate phosphonate by CH2, CCl2, CBr2 or CF2 groups, respecting specific geometry and bond distances. One magnesium ion is represented as green sphere. Amino acid R72 and the second magnesium ion are intentionally omitted for figure clarity. (a) Structure 1T05: distances between the O of the bridge and amino acids K65 and D113 are mentioned in dotted line. (c) and (d) steric hindrance is mentioned in full line. (e) Interactions are mentioned in dotted line.
Conclusion

Nine diphosphate analogues of PMEA have been designed as isostere of the parent diphosphorylated form, PMEApp. The benefit of stable P–C bonds replacing scissile P–O–C linkage constitutes an attractive interest to evaluate the electronic and stereochemical requirements for binding to relevant proteins. It was observed that HIV-RT does not extend the DNA primer with the synthesized compounds. Within this acyclic series, the replacement of the $\beta_{\gamma}$ bridge of the diphosphate phosphonate by CH$_2$, CHCl, CCl$_2$, CHBr, CBr$_2$, CHF or CF$_2$ groups has a drastic effect on the recognition by the HIV-RT.

Authors’ note

This article is dedicated to Dr. Gilles GOSSELIN on the occasion of his retirement.

Acknowledgments

We thank the “Fonds der Chemischen Industrie” for a post-doctoral fellowship (W. L.). We thank the “Agence Nationale de Recherche sur le Sida et les Hépatites Virales” for its financial support.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Supplementary material

Supplementary material (synthetic procedure and compounds characterization) is provided as a separate electronic file (PDF format) and was submitted along with the manuscript.

References